Dysbiosis and Regulation of Gut Microbiota in Type 2 Diabetes Mellitus

Type 2 diabetes mellitus is a serious metabolic disease having a high growth rate and becoming a global threat. An unhealthy lifestyle, food intake, and genetic susceptibility are the major factors responsible for this metabolic disorder. This disease results in hyperlipidemia, hyperglycemia, glucose intolerance, restricted insulin synthesis, and insulin resistance. Despite a variety of treatments currently available, cases of diabetes and resulting complications are on the rise. One promising approach to diabetes focuses on gut microflora and their associated metabolites. Gut microbiota has attracted widespread attention due to its crucial role in disease pathophysiology. This study explores the dysbiosis in the human gut microflora in Type 2 Diabetes Mellitus and how the gut microbiota influences metabolites related to T2DM. It also sheds light on early identification and targeted intervention for this. Understanding these mechanisms could potentially lead to more effective strategies for managing and preventing T2DM. The findings of our literature study are that gut microbiota can serve as biomarkers for early disease detection. Finally, we also highlight gut microecological therapeutic strategies focused on shaping the gut flora to emphasize the improvement of T2DM progression.

Authors

Institutions

Publication Details

Journal
Current Pharmaceutical Biotechnology
Published
2024-09-26
DOI
https://doi.org/10.2174/0113892010318580240910061534
Citations
2
Primary Topic
Gut microbiota and health
Type
article
Field-Weighted Citation Impact
0.47
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Dysbiosis and Regulation of Gut Microbiota in Type 2 Diabetes Mellitus

Minakshi, Antresh Kumar, Shaurya Prakash, Hemlata Kumari
2 citations
Current Pharmaceutical Biotechnology
Gut microbiota and health
0.47
article

Dysbiosis and Regulation of Gut Microbiota in Type 2 Diabetes Mellitus

Minakshi, Antresh Kumar, Shaurya Prakash, Hemlata Kumari
article en
2 citations

Abstract

Type 2 diabetes mellitus is a serious metabolic disease having a high growth rate and becoming a global threat. An unhealthy lifestyle, food intake, and genetic susceptibility are the major factors responsible for this metabolic disorder. This disease results in hyperlipidemia, hyperglycemia, glucose intolerance, restricted insulin synthesis, and insulin resistance. Despite a variety of treatments currently available, cases of diabetes and resulting complications are on the rise. One promising approach to diabetes focuses on gut microflora and their associated metabolites. Gut microbiota has attracted widespread attention due to its crucial role in disease pathophysiology. This study explores the dysbiosis in the human gut microflora in Type 2 Diabetes Mellitus and how the gut microbiota influences metabolites related to T2DM. It also sheds light on early identification and targeted intervention for this. Understanding these mechanisms could potentially lead to more effective strategies for managing and preventing T2DM. The findings of our literature study are that gut microbiota can serve as biomarkers for early disease detection. Finally, we also highlight gut microecological therapeutic strategies focused on shaping the gut flora to emphasize the improvement of T2DM progression.

Current Pharmaceutical BiotechnologyVol. 26(14)
Central University of Haryana (IN)
Zero hunger
Openalex Percentile: Top 35%
Gut microbiota and health
0.47
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Dysbiosis and Regulation of Gut Microbiota in Type 2 Diabetes Mellitus — Minakshi, Antresh Kumar, et al. · Current Pharmaceutical Biotechnology (2024) | TGRS Research Map | TGRS